GlassScriptPhysician profile
Gary A Thompson
NPI 1477545762
$3,813.47
in general payments reported to CMS, 2019-2025
33 companies · $610 in 2025
The $610 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $163 · 2021: $152 · 2022: $717 · 2023: $921 · 2024: $799 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $440.55 | 2019-2025 | Apretude |
| Merck Sharp & Dohme LLC | $440.49 | 2019-2025 | Belsomra, Steglatro, Gardasil 9 |
| Abbvie INC. | $396.47 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Corium, LLC | $389.82 | 2022-2024 | Azstarys |
| Amgen INC. | $246.88 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Pfizer INC. | $209.61 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.27 | 2019-2022 | |
| Lilly USA, LLC | $185.19 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $177.97 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Supernus Pharmaceuticals, INC. | $142.71 | 2022-2024 | Qelbree, Qelbree |
| Gilead Sciences, INC. | $134.40 | 2019-2025 | |
| Glaxosmithkline, LLC. | $128.64 | 2019-2024 | Arexvy, Shingrix |
| Neos Therapeutics, LP | $114.30 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $73.05 | 2023-2024 | Amvuttra |
| Tris Pharma INC | $68.38 | 2022-2024 | Dyanavel Xr |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $61.93 | 2024 | |
| Shire North American Group INC | $59.35 | 2019 | |
| Forte Bio-Pharma LLC | $30.59 | 2025 | Prolate, Tanlor, Nalocet |
| Kowa Pharmaceuticals America, INC. | $30.27 | 2020-2025 | Zoryve |
| Arbor Pharmaceuticals, INC. | $30.24 | 2019 | |
| Idorsia Pharmaceuticals US INC | $28.00 | 2022-2023 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $25.97 | 2025 | |
| Neurelis, INC. | $23.65 | 2024 | Valtoco |
| Sunovion Pharmaceuticals INC. | $22.30 | 2019 | |
| Daiichi Sankyo INC. | $21.76 | 2025 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.81 | 2024 | Caplyta |
| Electromed, INC. | $17.55 | 2025 | Smartvest |
| Phathom Pharmaceuticals, INC. | $17.27 | 2024 | Voquezna |
| Eisai INC. | $16.74 | 2020 | |
| Exact Sciences Corporation | $15.39 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $14.60 | 2025 | Wegovy |
| Adlon Therapeutics L.P. | $11.89 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.